PhaseBio Pharmaceuticals, Inc. (PHAS)
| Market Cap | 127.15M |
| Revenue (ttm) | 1.08M |
| Net Income (ttm) | n/a |
| Shares Out | 29.36M |
| EPS (ttm) | -2.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $4.33 |
| Previous Close | $4.19 |
| Change ($) | 0.14 |
| Change (%) | 3.34% |
| Day's Open | 4.16 |
| Day's Range | 4.16 - 4.38 |
| Day's Volume | 233,699 |
| 52-Week Range | 2.68 - 6.02 |
PHAS has an interesting platform whose proof of concept lead asset has considerable chance of approval. If that molecule goes through, others may follow based on the ELP platform.
Investors need to pay close attention to PhaseBio (PHAS) stock based on the movements in the options market lately.
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS--PhaseBio Provides Pemziviptadil (PB1046) Program Update
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #PhaseBio--PhaseBio Doses First Patients in Canada as part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Ef...
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Cardiology--PhaseBio to Present at the H.C.
PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -96.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Earnings--PhaseBio Pharmaceuticals Reports Recent Business Highlights and Second-Quarter 2020 Financial Results
PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ARDS--PhaseBio to Present at the William Blair Biotech Focus Conference 2020
PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.
PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) announced early on Friday that it has initiated its midstage study evaluating a treatment for the novel coronavirus.
MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc.
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ARDS--PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients
If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify severa...
PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) shares were skyrocketing Thursday after the company revealed it has received the go-ahead from the FDA for evaluating one of its lead assets for COV...
PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) shares jumped early on Thursday after the company announced that it received an authorization from the U.S.
PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -26.83% and -14.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
As of late, it has definitely been a great time to be an investor in PhaseBio Pharmaceuticals, Inc. (PHAS).
MALVERN, Pa. and SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commerc...
PB2452 granted PRIME Designation by the European Medicines Agency
PhaseBio to be responsible for all development, manufacturing and commercialization PhaseBio to be responsible for all development, manufacturing and commercialization
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS), which develops therapies for cardiopulmonary diseases, announced a financing agreement Friday that could provide the company with up to $120 millio...
PhaseBio to receive up to $120 million in development funding
MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -11.11% and -31.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...
Company Appoints Kristopher L. Hanson as Vice President, Head of Legal and Glen Burkhardt as Vice President of Human Resources Company Appoints Kristopher L. Hanson as Vice President, Head of...
MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and comme...
Preliminary Results from Supratherapeutic-Dose Ticagrelor Cohort Are Consistent with Earlier Phase 2a Cohorts and Previously Published Phase 1 Trial Preliminary Results from Supratherapeutic-D...
Results from three different assays, including VerifyNow® PRUTest®, demonstrate a high degree of correlation Results from three different assays, including VerifyNow® PRUTest®, demonstrate a h...
MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commerc...
Shares of PhaseBio Pharmaceuticals, Inc. jumped on Tuesday after the firm announced preliminary results from its mid-stage trial for dual antiplatelet therapy of the blood thinner ticagrelor a...
Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.
PhaseBio received Breakthrough Therapy Designation from the FDA based on positive phase 1 results using PB2452 as an anti-platelet agent for Brilinta.
The company made two major announcements in the last 24 hours.
FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.
PhaseBio Pharmaceuticals Inc. shares made a sizable gain on Tuesday morning after the U.S. Food and Drug Administration provided a critical update for the firm.
PhaseBio Pharmacueuticals Inc. shares rallied 28% in premarket trade Tuesday, after the company won U.S. Food and Drug Administration breakthrough therapy designation for PB2452, a novel rever...
Can you guess what these high-flying stocks have in common?
PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent
Shares of PhaseBio Pharmaceuticals Inc. more than doubled in premarket trade Monday, soaring 112% toward a record high.
PhaseBio Pharmaceuticals Inc. shares more than doubled on Monday after the firm released results from an early-stage clinical trial.
Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.
About PHAS
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial... [Read more...]
| Industry Biotechnology | IPO Date Oct 18, 2018 |
| CEO Jonathan Mow | Employees 50 |
| Stock Exchange NASDAQ | Ticker Symbol PHAS |
Analyst Forecasts
According to 6 analysts, the average rating for PHAS stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 211.78% from the latest price.